![Page 1: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/1.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
![Page 2: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/2.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Baseline Characteristics of Patients by Sex
![Page 3: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/3.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Changes in LDL and hs-CRP levels in women and men as stratified by randomization treatment group from baseline to final visit
![Page 4: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/4.jpg)
Q.A. Truong et al. CCQO 2011;4:328-336
Percentage of patients with achieved LDL and hs-CRP target levels
Percentage of patients with achieved LDL target levels of 100 mg/dL and 70 mg/dL (A) and with achieved hs-CRP 2 mg/LLDL 70 mg/dL (B) by randomized treatment group as stratified by sex at 30 days and at the final visit. A, All P<0.001 when comparing proportion of patients with achieved target LDL levels with atorvastatin versus pravastatin as stratified by women and men. A greater proportion of men reached target LDL levels with atorvastatin than did women (all P<0.001). In patients receiving pravastatin, the proportion of men and women who achieved target LDL levels was not different (all P<0.13).B, All P<0.015 when comparing proportions of patients with achieved hs-CRPLDL levels with treatment group as stratified by sex.
![Page 5: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/5.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Rate of Premature Discontinuation of Statin Therapy and Side Effects of High- Versus Standard-Dose
Statin as Stratified by Sex
![Page 6: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/6.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Kaplan-Meier curves of primary end point by study termination in women (A) and men (B)
![Page 7: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/7.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Hazard ratios between intensive-dose atorvastatin and standard-dose pravastatin therapy in women and men
![Page 8: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/8.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
Hazard ratios of the primary end point in women treated with intensive lipid-lowering therapy
(atorvastatin 80 mg) compared to standard lipid-lowering therapy (pravastatin 40 mg) therapy
![Page 9: Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336](https://reader036.vdocuments.us/reader036/viewer/2022081603/56814c13550346895db910cb/html5/thumbnails/9.jpg)
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336
WHAT THE STUDY ADDS